Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB. McDonagh CF, et al. Among authors: adams s. Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820. Epub 2012 Jan 16. Mol Cancer Ther. 2012. PMID: 22248472
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ Jr, Schoeberl B, Nielsen UB, Lugovskoy AA. Fitzgerald JB, et al. Among authors: adams s. Mol Cancer Ther. 2014 Feb;13(2):410-25. doi: 10.1158/1535-7163.MCT-13-0255. Epub 2013 Nov 26. Mol Cancer Ther. 2014. PMID: 24282274
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA. Camblin AJ, et al. Among authors: adams s. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16. Clin Cancer Res. 2018. PMID: 29549161
IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, Lai KC, Portwood S, Adams S, Sloss CM, Schuurhuis GJ, Ossenkoppele G, Wang ES, Pinkas J. Kovtun Y, et al. Among authors: adams s. Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27. Mol Cancer Ther. 2018. PMID: 29588393
Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
Bai C, Reid EE, Wilhelm A, Shizuka M, Maloney EK, Laleau R, Harvey L, Archer KE, Vitharana D, Adams S, Kovtun Y, Miller ML, Chari R, Keating TA, Yoder NC. Bai C, et al. Among authors: adams s. Bioconjug Chem. 2020 Jan 15;31(1):93-103. doi: 10.1021/acs.bioconjchem.9b00777. Epub 2019 Dec 10. Bioconjug Chem. 2020. PMID: 31747250 Free article.
Timing of Red Blood Cell Transfusions and Occurrence of Necrotizing Enterocolitis: A Secondary Analysis of a Randomized Clinical Trial.
Salas AA, Gunn E, Carlo WA, Bell EF, Das A, Josephson CD, Patel RM, Tan S, Kirpalani H; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network. Salas AA, et al. JAMA Netw Open. 2024 May 1;7(5):e249643. doi: 10.1001/jamanetworkopen.2024.9643. JAMA Netw Open. 2024. PMID: 38700862 Clinical Trial.
3,678 results